Lee S P, Wallace L E, Mackett M, Arrand J R, Searle P F, Rowe M, Rickinson A B
Department of Cancer Studies, University of Birmingham, UK.
Int Immunol. 1993 May;5(5):451-60. doi: 10.1093/intimm/5.5.451.
Epstein-Barr virus (EBV) transformed B lymphoblastoid cell lines (LCL) efficiently process exogenous antigens for MHC class II-restricted presentation via the chloroquine-sensitive endosomal pathway. Using MHC class II-restricted T cell clones specific for EBV structural proteins, however, we frequently observed significant responses to autologous LCL cells without the addition of exogenous virus. Such responses were reduced by pre-treating the LCL with acyclovir (ACV), a drug blocking productive EBV infection. This suggested T cell recognition of antigen synthesized by LCL cells spontaneously entering virus productive cycle, and led us to question by what route(s) MHC class II-restricted presentation of endogenously synthesized virion proteins was occurring. Cell sorting experiments, using the viral envelope glycoprotein gp340 as a surface marker of productively-infected cells, confirmed that stimulatory activity lay within the gp340-positive fraction. However, closer analysis revealed that most of these cells were not productively-infected but were EBV receptor-positive and had bound released virus. We infer that receptor-mediated delivery of released virus into the endosomal pathway is one route whereby an LCL can present endogenously synthesized EBV proteins on MHC class II molecules. To ask whether another, more direct, route of processing was possible, we used a recombinant vaccinia viral vector to express gp340 de novo in ACV-treated LCLs. Significantly, these cells presented the endogenously synthesized antigen to autologous gp340-specific T cell clones via a chloroquine-resistant pathway. In the same experiments, vaccinia-mediated expression of a signal peptide-deleted form of gp340 did not lead to T cell stimulation, suggesting that this second route of processing required entry of endogenously synthesized antigen into the endoplasmic reticulum.
爱泼斯坦-巴尔病毒(EBV)转化的B淋巴母细胞系(LCL)可通过对氯喹敏感的内体途径有效处理外源性抗原,用于MHC II类限制的呈递。然而,使用针对EBV结构蛋白的MHC II类限制的T细胞克隆,我们经常观察到在不添加外源性病毒的情况下,对自体LCL细胞有显著反应。用阿昔洛韦(ACV)预处理LCL可减少这种反应,ACV是一种阻断EBV有效感染的药物。这表明T细胞识别自发进入病毒生产周期的LCL细胞合成的抗原,并使我们质疑内源性合成的病毒体蛋白的MHC II类限制呈递是通过何种途径发生的。利用病毒包膜糖蛋白gp340作为有效感染细胞的表面标志物进行细胞分选实验,证实刺激活性存在于gp340阳性部分。然而,进一步分析发现,这些细胞中的大多数并非有效感染,而是EBV受体阳性并结合了释放的病毒。我们推断,受体介导的释放病毒进入内体途径是LCL在MHC II类分子上呈递内源性合成的EBV蛋白的一种途径。为了探究是否可能存在另一种更直接的加工途径,我们使用重组痘苗病毒载体在经ACV处理的LCL中从头表达gp340。值得注意的是,这些细胞通过对氯喹耐药的途径将内源性合成的抗原呈递给自体gp340特异性T细胞克隆。在相同实验中,痘苗介导的gp340信号肽缺失形式的表达未导致T细胞刺激,这表明这种第二种加工途径需要内源性合成的抗原进入内质网。